These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21950291)

  • 1. Lipoatrophy in patients with AIDS: treatment with polymethylmethacrylate in Amazonas, Brazil.
    Orsi AT; Miranda AE; Souza AC; Silva LC; Dias GR; Talhari C; Talhari S; Santos M
    Int J Dermatol; 2011 Oct; 50(10):1255-8. PubMed ID: 21950291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of facial lipoatrophy treatment with polymethyl methacrylate in AIDS patients as measured by four quality-of-life questionnaires.
    Warde M; Gragnani A; Gomes H; Hochman B; Ferreira LM
    Int J STD AIDS; 2011 Oct; 22(10):596-9. PubMed ID: 21998182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
    Piquet M; Brignol L; Chatelain B; Rey D; Ricbourg B; Meyer C
    Rev Stomatol Chir Maxillofac; 2007 Dec; 108(6):496-504. PubMed ID: 17675198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of facial lipoatrophy with polymethylmethacrylate among patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): impact on the quality of life.
    Quintas RC; de França ER; de Petribú KC; Ximenes RA; Quintas LF; Cavalcanti EL; Kitamura MA; Magalhães KA; Paiva KC; Filho DB
    Int J Dermatol; 2014 Apr; 53(4):497-502. PubMed ID: 24602032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
    Tin EE; Bowonwatanuwong C; Desakorn V; Wilairatana P; Krudsood S; Pitisuttithum P
    Southeast Asian J Trop Med Public Health; 2005 Mar; 36(2):362-9. PubMed ID: 15916042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda.
    van Griensven J; De Naeyer L; Mushi T; Ubarijoro S; Gashumba D; Gazille C; Zachariah R
    Trans R Soc Trop Med Hyg; 2007 Aug; 101(8):793-8. PubMed ID: 17467756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An index for staging facial lipoatrophy and evaluation of the efficacy of the treatment with polymethylmethacrylate in HIV/AIDS patients: a pilot study.
    Serra MS; Oyafuso LK; Trope BM; Munhoz Leite OH; Ramos-e-Silva M
    J Eur Acad Dermatol Venereol; 2013 Aug; 27(8):990-6. PubMed ID: 22774979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of facial lipoatrophy using autologous fat transplants in HIV-infected adolescents.
    Dollfus C; Blanche S; Trocme N; Funck-Brentano I; Bonnet F; Levan P
    HIV Med; 2009 May; 10(5):263-8. PubMed ID: 19178590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin.
    Olawumi HO; Olatunji PO; Salami AK; Odeigah L; Iseniyi JO
    Niger J Clin Pract; 2008 Dec; 11(4):312-5. PubMed ID: 19320401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effect of polyalkylimide gel injections on severity of facial lipoatrophy and quality of life of HIV-positive patients.
    Karim RB; de Lint CA; van Galen SR; van Rozelaar L; Nieuwkerk PT; Askarizadeh E; Hage JJ
    Aesthetic Plast Surg; 2008 Nov; 32(6):873-8. PubMed ID: 18551339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
    McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
    Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soft tissue augmentation with PMMA-microspheres for the treatment of HIV-associated buttock lipodystrophy.
    Serra MS; Gonçalves LZ; Ramos-e-Silva M
    Int J STD AIDS; 2015 Mar; 26(4):279-84. PubMed ID: 24855130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host factors may be more important than choice of antiretrovirals in the development of lipoatrophy.
    McComsey G; Maa JF
    AIDS Read; 2003 Nov; 13(11):539-42, 559. PubMed ID: 14649623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive.
    Bergersen BM; Sandvik L; Ellingsen I; Bruun JN
    HIV Med; 2005 Jul; 6(4):260-7. PubMed ID: 16011531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery of fat following a switch to nucleoside reverse transcriptase inhibitor-sparing therapy in patients with lipoatrophy: results from the 96-week randomized ANRS 108 NoNuke Trial.
    Valantin MA; Lanoy E; Bentata M; Kalmykova O; Boutekadjirt A; Allavena C; Rozenbaum W; Peytavin G; Amellal B; Calvez V; Costagliola D; Katlama C;
    HIV Med; 2008 Oct; 9(8):625-35. PubMed ID: 18624724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
    Skiest DJ; Su Z; Havlir DV; Robertson KR; Coombs RW; Cain P; Peterson T; Krambrink A; Jahed N; McMahon D; Margolis DM;
    J Infect Dis; 2007 May; 195(10):1426-36. PubMed ID: 17436222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistence of lipoatrophy after a four-year long interruption of antiretroviral therapy for HIV1 infection: case report.
    Parruti G; Toro GM
    BMC Infect Dis; 2005 Oct; 5():80. PubMed ID: 16202141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy.
    Galli M; Ridolfo AL; Adorni F; Cappelletti A; Morelli P; Massetto B; Piazza M; Gianelli E; Vaccarezza M; Gervasoni C; Moroni M
    Antivir Ther; 2003 Aug; 8(4):347-54. PubMed ID: 14518704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polyacrylamide gel treatment of antiretroviral therapy-induced facial lipoatrophy in HIV patients.
    Mansor S; Breiting VB; Dahlstrøm K; Andersen AB; Andersen O; Christensen LH
    Aesthetic Plast Surg; 2011 Oct; 35(5):709-16. PubMed ID: 21359981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral therapy in AIDS patients with CMV disease: impact on the survival and long-term treatment outcome.
    Sungkanuparph S; Chakriyanuyok T; Butthum B
    J Infect; 2008 Jan; 56(1):40-3. PubMed ID: 18037166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.